These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 34016077)

  • 21. The placebo effect in thyroid cancer: a meta-analysis.
    Llavero-Valero M; Guillén-Grima F; Zafon C; Galofré JC
    Eur J Endocrinol; 2016 Apr; 174(4):465-72. PubMed ID: 26764417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours.
    Sowa-Staszczak A; Pach D; Kunikowska J; Krolicki L; Stefanska A; Tomaszuk M; Buziak-Bereza M; Mikolajczak R; Matyja M; Gilis-Januszewska A; Jabrocka-Hybel A; Trofimiuk M; Hubalewska-Dydejczyk A
    Endokrynol Pol; 2011; 62(5):392-400. PubMed ID: 22069099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radioiodine Remnant Ablation for Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis.
    James DL; Ryan ÉJ; Davey MG; Quinn AJ; Heath DP; Garry SJ; Boland MR; Young O; Lowery AJ; Kerin MJ
    JAMA Otolaryngol Head Neck Surg; 2021 Jun; 147(6):544-552. PubMed ID: 33792650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study.
    Baum RP; Kluge AW; Kulkarni H; Schorr-Neufing U; Niepsch K; Bitterlich N; van Echteld CJ
    Theranostics; 2016; 6(4):501-10. PubMed ID: 26941843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).
    Leboulleux S; Kapiteijn E; Litière S; Schöffski P; Godbert Y; Rodien P; Jarzab B; Salvatore D; Zanetta S; Capdevila J; Bastholt L; De La Fouchardiere C; Lalami Y; Bardet S; Cornélis F; Dedecjus M; Links T; Sents W; Schlumberger M; Locati DL; Newbold K
    Front Endocrinol (Lausanne); 2024; 15():1403687. PubMed ID: 39015176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High clinical and morphologic response using
    Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 99mTc-EDDA/HYNIC-TOC in the diagnosis of differentiated thyroid carcinoma refractory to radioiodine treatment.
    Czepczyński R; Gryczyńska M; Ruchała M
    Nucl Med Rev Cent East Eur; 2016; 19(2):67-73. PubMed ID: 27479883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis.
    Budiawan H; Salavati A; Kulkarni HR; Baum RP
    Am J Nucl Med Mol Imaging; 2013; 4(1):39-52. PubMed ID: 24380044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Targeted radionuclide therapy for patients with metastatic medullary thyroid carcinoma].
    Gao ZR; An R; Zhang YX; Biersack HJ
    Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):621-4. PubMed ID: 17236560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a systematic review and meta-analysis.
    Feng G; Luo Y; Zhang Q; Zeng F; Xu J; Zhu J
    Endocrine; 2020 Apr; 68(1):56-63. PubMed ID: 31955344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
    Kraeber-Bodéré F; Rousseau C; Bodet-Milin C; Ferrer L; Faivre-Chauvet A; Campion L; Vuillez JP; Devillers A; Chang CH; Goldenberg DM; Chatal JF; Barbet J
    J Nucl Med; 2006 Feb; 47(2):247-55. PubMed ID: 16455630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy.
    Grossrubatscher E; Fanciulli G; Pes L; Sesti F; Dolci C; de Cicco F; Colao A; Faggiano A; Nike Group
    J Clin Med; 2020 Oct; 9(11):. PubMed ID: 33138305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using.
    Waldherr C; Schumacher T; Pless M; Crazzolara A; Maecke HR; Nitzsche EU; Haldemann A; Mueller-Brand J
    Nucl Med Commun; 2001 Jun; 22(6):673-8. PubMed ID: 11403179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is there a role for peptide receptor radionuclide therapy in medullary thyroid cancer?
    Vaisman F; Rosado de Castro PH; Lopes FP; Kendler DB; Pessoa CH; Bulzico DA; de Carvalho Leal D; Vilhena B; Vaisman M; Carneiro M; Corbo R
    Clin Nucl Med; 2015 Feb; 40(2):123-7. PubMed ID: 25546220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
    Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
    Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hematologic toxicity in patients treated with sunitinib for advanced thyroid cancer.
    Gkountouvas A; Kostoglou-Athanassiou I; Veniou E; Repousis P; Ziras N; Kaldrimidis P
    Thyroid; 2010 Jun; 20(6):597-600. PubMed ID: 20553195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Effect of Radioactive Iodine Therapy on Ovarian Function and Fertility in Female Thyroid Cancer Patients: A Systematic Review and Meta-Analysis.
    Piek MW; Postma EL; van Leeuwaarde R; de Boer JP; Bos AME; Lok C; Stokkel M; Filipe MD; van der Ploeg IMC
    Thyroid; 2021 Apr; 31(4):658-668. PubMed ID: 33012254
    [No Abstract]   [Full Text] [Related]  

  • 38. Long-term results of PRRT in advanced bronchopulmonary carcinoid.
    Mariniello A; Bodei L; Tinelli C; Baio SM; Gilardi L; Colandrea M; Papi S; Valmadre G; Fazio N; Galetta D; Paganelli G; Grana CM
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):441-52. PubMed ID: 26392198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. (131)I treatment in Differentiated Thyroid Cancer and End-Stage Renal Disease.
    Ortega AJ; Vázquez RG; Cuenca JI; Brocca MA; Castilla J; Martínez JM; González EN
    Rev Esp Med Nucl Imagen Mol; 2016; 35(1):29-33. PubMed ID: 26144699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.